Abstract
Turoctocog alfa pegol (N8-GP) is an extended half-life factor VIII molecule for use in adults and children with haemophilia A (HA) for routine prophylaxis, on-demand treatment including control of bleeding episodes, and perioperative management. This study aims to understand the real-world experience of patients with HA receiving N8-GP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
